Latest AusBiotech News | Page 2

Carina Biotech doses first patient in Phase 1/2a trial of LGR5-Targeted CAR-T cell therapy
Neuren Pharmaceuticals announces top-line results of Phase 2 NNZ-2591 trial
Year of collective success: 2023 in review
AusBiotech announces Acting CEO
CMAX Clinical Research preparing to celebrate three decades of continuous operations
Brooker Consulting launches two new initiative for life science sector
AusBiotech calls for journal articles 14 December
FDA grants fast-track designation for EnGeneIC’s pancreatic cancer candidate
Prescient announces the results of PTX-100 Phase 1b study in T-cell lymphoma patients
New leadership for Health Security Systems Australia
Victorian Government backs the development of Cyban’s brain injury technology
Australia’s clinical trial sector connects at AusBiotech 2023
AusBiotech energised by new Board appointments
Cynata Therapeutics secures approval for Phase 2 trial in Turkey
Microba Life Sciences announces results of successful Phase IBD trial
Telix says the first patient dosed in European early access program for TLX250-CDx
Neuren Pharmaceuticals completes enrolment in Pitt Hopkins syndrome Phase 2 trial
Australia’s Cell and Gene Catalyst calls for Expressions of Interest
OncoSil Medical onboards first patient in the PANCOSIL clinical trial
Korean regulator approves Amplia Therapeutics’ pancreatic cancer trial
Clarity’s theranostic prostate cancer trial progresses at the highest dose level cohort
Microba completes stage one screening for its autoimmune disease program
National Reconstruction Fund (NRF) investment mandate released
Federal government backs the development of treatment for childhood brain cancer
Dimerix’s ACTION3 investigational new drug approved in China
Medical science a ‘priority area’ for new Industry Growth Program
AusBiotech weighs in on Australia’s RNA future
The Cell and Gene Catalyst call for change in submission to scope of practice review
Alterity Therapeutics raises $4.8 million in new placement
Orthocell announces final positive results of cell therapy in ‘tennis elbow’ study
Anteris reports positive 30-Day haemodynamic results from trial
Biotech headed to Hill for AusBiotech’s Policy Forum
Alterity Therapeutics announces presentation of new data for ATH434
US FDA grants Argenica Therapeutics’ ARG-007 orphan drug designation
Neuren Pharmaceuticals completes Phelan-McDermid syndrome Phase 2 trial 
University of Queensland to establish world-leading mRNA laboratory
Telix says first patient dosed in ProstACT study of prostate cancer candidate
New report demonstrates benefit of long-term policy commitment
Clarity says recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
Imugene says next cohort reached in intravenous arms of monotherapy and combination study
New report quantifies the importance of R&D Tax Incentive on Australian economy
AusBiotech 2023 underway in Queensland
AusBiotech Board election result announced
AgTech Showcase kicks off month of innovation
New report quantifies impact of R&D Tax Incentive in Australia’s life sciences sector
It’s in our DNA: Australia’s biggest week in life sciences to advance biotech
Opthea announces leadership transition with the appointment of US-based executives